Cover Image
市場調查報告書

單株抗體(mAb)市場規模與預測:各來源(嵌合,鼠,人體化,人),各生產類型,適用(癌症,自體免疫疾病,發炎性疾病,感染疾病,微生物及病毒疾病),各終端用戶,及市場區隔預測

Monoclonal Antibodies (mAbs) Market Analysis By Source (Chimeric, Murine, Humanized, Human), By Type of Production, By Indication (Cancer, Autoimmune, Inflammatory, Infectious, Microbial, Viral Diseases), By End-use And Segment Forecasts, 2013 - 2024

出版商 Grand View Research, Inc. 商品編碼 398908
出版日期 內容資訊 英文 115 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
單株抗體(mAb)市場規模與預測:各來源(嵌合,鼠,人體化,人),各生產類型,適用(癌症,自體免疫疾病,發炎性疾病,感染疾病,微生物及病毒疾病),各終端用戶,及市場區隔預測 Monoclonal Antibodies (mAbs) Market Analysis By Source (Chimeric, Murine, Humanized, Human), By Type of Production, By Indication (Cancer, Autoimmune, Inflammatory, Infectious, Microbial, Viral Diseases), By End-use And Segment Forecasts, 2013 - 2024
出版日期: 2016年11月02日 內容資訊: 英文 115 Pages
簡介

本報告提供單株抗體(mAb)市場相關調查,市場趨勢與各來源,各生產類型,適用,各最終用途,及各地區預測,競爭趨勢,及加入此市場的主要企業簡介等彙整資料。

第1章 調查方法與範圍

第2章 摘要整理

第3章 市場概要

第4章 市場變數,趨勢,範圍

  • 市場區隔和範圍
    • 促進要素分析
    • 阻礙要素分析
  • 滲透率與成長預測製圖
  • SWOT分析
  • 波特五力分析

第5章 市場類別1:各來源預測與趨勢分析

  • 單株抗體市場
  • 嵌合
  • 人體化

第6章 市場類別2:各生產類型預測與趨勢分析

  • 各生產類型趨勢分析
  • 體外
  • 體內

第7章 市場類別3:各適應症預測與趨勢分析

  • 各疾病趨勢分析
  • 癌症
  • 自體免疫疾病
  • 發炎性疾病
  • 感染疾病
  • 微生物疾病
  • 病毒疾病

第8章 市場類別4:各最終用途預測與趨勢分析

  • 各最終用途趨勢分析
  • 醫院
  • 研究機關
  • 其他

第9章 市場類別3:各地區預測與趨勢分析

  • 各地區趨勢分析
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東·非洲

第10章 競爭環境

  • 策略性架構
  • 市場進入分類
  • 企業簡介
    • Novartis International
    • Pfizer
    • GlaxoSmithKline Plc
    • Amgen Inc.
    • Merck & Co., Inc.
    • 第一三共株式會社
    • Abbott Laboratories
    • AstraZeneca plc
    • Eli Lilly
    • Johnson & Johnson
    • Bayer AG
    • Bristol Myers Squibb
    • F.Hoffman-La Roche Ltd.
    • Mylan N.V.
    • Biogen Idec Inc.
    • Thermo Fisher Scientific
    • Novo Nordisk
    • Sanofi
    • Genzyme

圖表

目錄
Product Code: GVR-1-68038-280-8

The global monoclonal antibodies (mAbs) market was valued at USD 85.4 billion in 2015 and is expected to reach a value of USD 138.6 billion by 2024. Increasing R&D pertaining to the development of therapeutic mAbs coupled with supportive government initiatives is expected to drive the monoclonal antibodies market growth over the forecast period.

Increasing demand for personalized medicine is a vital factor responsible for the increasing development of therapeutic antibodies to provide targeted therapies as every individual responds in a different manner to a particular treatment. Moreover, related benefits of using mAbs for therapeutic purposes, including fewer adverse effects, homogeneity, specificity, and large-scale production, are contributing toward significant market growth.

In addition, the government initiatives to enable cost-effective production of mAbs is anticipated to propel the emergence of this sector over the forecast period. For instance, the biomanufacturing initiative byNational Institute of Standards and Technology in the U.S. provides scientifically sound regulatory guidelines to ensure effective and safe manufacturing of protein therapeutics and to support biopharmaceutical manufacturers in offering low-cost and high-quality protein drugs across the globe.

Further Key Findings from the Study Suggest:

  • Human-based mAbs segment is predicted to grow at a lucrative CAGR in the coming years due to their associated benefits and numerous R&D activities conducted for further development of human mAbs. Large number of mAbs of human origin are in phase III clinical trial for cancer treatment
  • In vitro production of mAbs is anticipated to show the fastest growth owing to its wide-scale adoption by biologics manufacturers due to its greater efficiency in cost and time
  • The research institute segment is anticipated to exhibit profitable growth due to increasing R&D efforts in the biotech industry as monoclonal antibodies have emerged as a major class of therapeutics for several human diseases, particularly immunological infectious diseases and cancer
  • The Asia pacific region has significant growth potential due to rising government initiatives in this region supporting the use of mAbs for research and treatment purposes coupled with the surge in sponsored R&D projects for the development of cost-effective therapeutic mAbs.
  • For instance, government-led fund providers, such as National Natural Science Foundation and National Basic Research Program of China, offer financial support to enterprises and universities to conduct mAb research and development.
  • The key players serving the monoclonal antibodies market arePfizer, Inc., GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc, Amgen, Inc., Abbott Laboratories, AstraZeneca, Eli Lilly and Company, Mylan N.V., Daiichi Sankyo Company, Ltd., Bayer AG, Bristol Myers Squibb Co.,Johnson & Johnson Services, Inc., Biogen Inc., Thermo Fisher Scientific, Inc., Sanofi Genzyme, F. Hoffmann-La Roche Ltd., and Novo Nordisk A/S.
  • The introduction of advanced methods for mAb production further encourages the pharmaceutical companies to build their own product pipeline. According to a study published by NCBI at the end of 2013, approximately 816 companies were involved in therapeutic protein research.

Table of Contents

Chapter 1. Research Methodology & Scope

  • 1.1. Region Wise Market Calculation
    • 1.1.1. Region Wise Market: Base Estimates
    • 1.1.2. Global Market: CAGR Calculation
  • 1.2. Region based segment share calculation
  • 1.3. List of Secondary Sources

Chapter 2. Executive Summary

Chapter 3. Market Snapshot

Chapter 4. Market Variables, Trends & Scope

  • 4.1. Market segmentation & scope
    • 4.1.1. Market Driver Analysis
      • 4.1.1.1. Increasing incidences of chronic diseases
      • 4.1.1.2. Technological advancements
      • 4.1.1.3. Growing awareness levels
  • 4.2. Market Restraint Analysis
      • 4.2.1.1. High cost of therapeutic mAbs
  • 4.3. Penetration & growth prospect mapping
  • 4.4. Monoclonal Antibodies-SWOT Analysis, By Factor(political & legal, economic and technological)
  • 4.5. Industry Analysis-Porter's

Chapter 5. Market Categorization 1: Source Type Estimates & Trend Analysis

  • 5.1. Monoclonal antibodies market: Source type movement analysis
  • 5.2. Murine
    • 5.2.1. Murine market, 2013-2024(USD Billion)
  • 5.3. Chimeric
    • 5.3.1. Chimeric market, 2013-2024(USD Billion)
  • 5.4. Humanized
    • 5.4.1. Humanized market, 2013-2024(USD Billion)
  • 5.5. Human
      • 5.5.1.1. Human market, 2013-2024(USD Billion)

Chapter 6. Market Categorization 2: Production Type Estimates & Trend Analysis

  • 6.1. Monoclonal antibodies market: Production type movement analysis
  • 6.2. In vitro
    • 6.2.1. In vitro market, 2013-2024(USD Billion)
  • 6.3. In vivo
    • 6.3.1. In vivo market, 2013-2024(USD Billion)

Chapter 7. Market Categorization 3: Indication Estimates & Trend Analysis

  • 7.1. Monoclonal antibodies market: Disease movement analysis
  • 7.2. Cancer
    • 7.2.1. Cancer Market, 2013-2024(USD Billion)
  • 7.3. Autoimmune diseases
    • 7.3.1. Autoimmune diseases market, 2013-2024(USD Billion)
  • 7.4. Inflammatory diseases
    • 7.4.1. Inflammatory diseases market, 2013-2024(USD Billion)
  • 7.5. Infectious diseases
    • 7.5.1. Infectious diseases market, 2013-2024(USD Billion)
  • 7.6. Microbial diseases
    • 7.6.1. Microbial diseases market, 2013-2024(USD Billion)
  • 7.7. Others
    • 7.7.1. Others diseases market, 2013-2024(USD Billion)

Chapter 8. Market Categorization 4: End-Use Estimates & Trend Analysis

  • 8.1. Monoclonal antibodies market: End-use movement analysis
  • 8.2. Hospitals
    • 8.2.1. Hospitals market, 2013-2024(USD Billion)
  • 8.3. Research Institutes
    • 8.3.1. Research institutes market, 2013-2024(USD Billion)
  • 8.4. Others
    • 8.4.1. Others market, 2013-2024(USD Billion)

Chapter 9. Market Categorization 5: Regional Estimates & Trend Analysis, by Source Type, Production Type, Indication & End-Use

  • 9.1. Monoclonal antibodies market shares by region, 2015 & 2024
  • 9.2. North America
    • 9.2.1. North America Monoclonal antibodies market estimates and forecasts, 2013-2024
    • 9.2.2. U.S.
      • 9.2.2.1. U.S. monoclonal antibodies market estimates and forecasts, 2013-2024
    • 9.2.3. Canada
      • 9.2.3.1. Canada monoclonal antibodies market estimates and forecasts, 2013-2024
  • 9.3. Europe
      • 9.3.1.1. Europe monoclonal antibodies market estimates and forecasts, 2013-2024
    • 9.3.2. Germany
      • 9.3.2.1. Germany monoclonal antibodies market estimates and forecasts, 2013-2024
    • 9.3.3. UK
      • 9.3.3.1. UK monoclonal antibodies market estimates and forecasts, 2013-2024
  • 9.4. Asia Pacific
      • 9.4.1.1. Asia Pacific monoclonal antibodies market estimates and forecasts, 2013-2024
    • 9.4.2. Japan
      • 9.4.2.1. Japan monoclonal antibodies market estimates and forecasts, 2013-2024
    • 9.4.3. China
      • 9.4.3.1. China monoclonal antibodies market estimates and forecasts, 2013-2024
    • 9.4.4. India
      • 9.4.4.1. India monoclonal antibodies market estimates and forecasts, 2013-2024
  • 9.5. Latin America
      • 9.5.1.1. Latin America monoclonal antibodies market estimates and forecasts, 2013-2024
    • 9.5.2. Brazil
      • 9.5.2.1. Brazil monoclonal antibodies market estimates and forecasts, 2013-2024
    • 9.5.3. Mexico
      • 9.5.3.1. Mexico monoclonal antibodies market estimates and forecasts, 2013-2024
  • 9.6. MEA
      • 9.6.1.1. MEA monoclonal antibodies market estimates and forecasts, 2013-2024
    • 9.6.2. South Africa
      • 9.6.2.1. South Africa Monoclonal antibodies market estimates and forecasts, 2013-2024

Chapter 10. Competitive Landscape

  • 10.1. Strategy framework
  • 10.2. Market participation categorization
  • 10.3. Company Profiles
    • 10.3.1. Novartis International
      • 10.3.1.1. Company Overview
      • 10.3.1.2. Financial Performance
      • 10.3.1.3. Product Benchmarking
      • 10.3.1.4. Strategic Initiatives
    • 10.3.2. Pfizer
      • 10.3.2.1. Company Overview
      • 10.3.2.2. Financial Performance
      • 10.3.2.3. Product Benchmarking
      • 10.3.2.4. Strategic Initiatives
    • 10.3.3. GlaxoSmithKline Plc
      • 10.3.3.1. Company Overview
      • 10.3.3.2. Financial Performance
      • 10.3.3.3. Product Benchmarking
      • 10.3.3.4. Strategic Initiatives
    • 10.3.4. Amgen Inc.
      • 10.3.4.1. Company Overview
      • 10.3.4.2. Financial Performance
      • 10.3.4.3. Product Benchmarking
      • 10.3.4.4. Strategic Initiatives
    • 10.3.5. Merck & Co., Inc.
      • 10.3.5.1. Company Overview
      • 10.3.5.2. Financial Performance
      • 10.3.5.3. Product Benchmarking
      • 10.3.5.4. Strategic Initiatives
    • 10.3.6. Daiichi Sankyo
      • 10.3.6.1. Company Overview
      • 10.3.6.2. Financial Performance
      • 10.3.6.3. Product Benchmarking
      • 10.3.6.4. Strategic Initiatives
    • 10.3.7. Abbott Laboratories
      • 10.3.7.1. Company Overview
      • 10.3.7.2. Financial Performance
      • 10.3.7.3. Product Benchmarking
      • 10.3.7.4. Strategic Initiatives
    • 10.3.8. AstraZeneca plc
      • 10.3.8.1. Company Overview
      • 10.3.8.2. Financial Performance
      • 10.3.8.3. Product Benchmarking
      • 10.3.8.4. Strategic Initiatives
    • 10.3.9. Eli Lilly
      • 10.3.9.1. Company Overview
      • 10.3.9.2. Financial Performance
      • 10.3.9.3. Product Benchmarking
      • 10.3.9.4. Strategic Initiatives
    • 10.3.10. Johnson & Johnson
      • 10.3.10.1. Company Overview
      • 10.3.10.2. Financial Performance
      • 10.3.10.3. Product Benchmarking
      • 10.3.10.4. Strategic Initiatives
    • 10.3.11. Bayer AG
      • 10.3.11.1. Company Overview
      • 10.3.11.2. Financial Performance
      • 10.3.11.3. Product Benchmarking
      • 10.3.11.4. Strategic Initiatives
    • 10.3.12. Bristol Myers Squibb
      • 10.3.12.1. Company Overview
      • 10.3.12.2. Financial Performance
      • 10.3.12.3. Product Benchmarking
      • 10.3.12.4. Strategic Initiatives
    • 10.3.13. F.Hoffman-La Roche Ltd.
      • 10.3.13.1. Company Overview
      • 10.3.13.2. Financial Performance
      • 10.3.13.3. Product Benchmarking
      • 10.3.13.4. Strategic Initiatives
    • 10.3.14. Mylan N.V.
      • 10.3.14.1. Company Overview
      • 10.3.14.2. Financial Performance
      • 10.3.14.3. Product Benchmarking
      • 10.3.14.4. Strategic Initiatives
    • 10.3.15. Biogen Idec Inc.
      • 10.3.15.1. Company Overview
      • 10.3.15.2. Financial Performance
      • 10.3.15.3. Product Benchmarking
      • 10.3.15.4. Strategic Initiatives
    • 10.3.16. Thermo Fisher Scientific
      • 10.3.16.1. Company Overview
      • 10.3.16.2. Financial Performance
      • 10.3.16.3. Product Benchmarking
      • 10.3.16.4. Strategic Initiatives
    • 10.3.17. Novo Nordisk
      • 10.3.17.1. Company Overview
      • 10.3.17.2. Financial Performance
      • 10.3.17.3. Product Benchmarking
      • 10.3.17.4. Strategic Initiatives
    • 10.3.18. Sanofi
      • 10.3.18.1. Company Overview
      • 10.3.18.2. Financial Performance
      • 10.3.18.3. Product Benchmarking
      • 10.3.18.4. Strategic Initiatives
    • 10.3.19. Genzyme
      • 10.3.19.1. Company Overview
      • 10.3.19.2. Financial Performance
      • 10.3.19.3. Product Benchmarking
      • 10.3.19.4. Strategic Initiatives

List of Tables

  • TABLE 1: Country share estimation
  • TABLE 2: North America monoclonal antibodies market, by source type , 2013 - 2024 (USD Billion)
  • TABLE 3: North America monoclonal antibodies market, by production type, 2013 - 2024 (USD Billion)
  • TABLE 4: North America monoclonal antibodies market, by indication, 2013 - 2024 (USD Billion)
  • TABLE 5: North America monoclonal antibodies market, by end-use, 2013 - 2024 (USD Billion)
  • TABLE 6: U.S. monoclonal antibodies market, by source type, 2013 - 2024 (USD billion)
  • TABLE 7: U.S. monoclonal antibodies market, by production type, 2013 - 2024 (USD Billion)
  • TABLE 8: U.S. monoclonal antibodies market, by indication, 2013 - 2024 (USD Billion)
  • TABLE 9: U.S. monoclonal antibodies market, by end-use, 2013 - 2024 (USD Billion)
  • TABLE 10: Canada monoclonal antibodies market, by source type, 2013 - 2024 (USD Billion)
  • TABLE 11: Canada monoclonal antibodies market, by production type, 2013 - 2024 (USD Billion)
  • TABLE 12: Canada monoclonal antibodies market, by indication, 2013 - 2024 (USD Billion)
  • TABLE 13: Canada monoclonal antibodies market, by end-use, 2013 - 2024 (USD Billion)
  • TABLE 14: Europe monoclonal antibodies market, by source type, 2013 - 2024 (USD Billion)
  • TABLE 15: Europe monoclonal antibodies market, by production type, 2013 - 2024 (USD Billion)
  • TABLE 16: Europe monoclonal antibodies market, by production type, 2013 - 2024 (USD Billion)
  • TABLE 17: Europe monoclonal antibodies market, by indication, 2013 - 2024 (USD Billion)
  • TABLE 18: Europe monoclonal antibodies market, by end-use, 2013 - 2024 (USD Billion)
  • TABLE 19: Germany monoclonal antibodies market, by source type, 2013 - 2024 (USD Billion)
  • TABLE 20: Germany monoclonal antibodies market, by production type, 2013 - 2024 (USD Billion)
  • TABLE 21: Germany monoclonal antibodies market, by indication, 2013 - 2024 (USD Billion)
  • TABLE 22: Germany monoclonal antibodies market, by end-use, 2013 - 2024 (USD Billion)
  • TABLE 23: UK monoclonal antibodies market, by source type , 2013 - 2024 (USD Billion)
  • TABLE 24: UK monoclonal antibodies market, by production type, 2013 - 2024 (USD Billion)
  • TABLE 25: UK monoclonal antibodies market, by indication, 2013 - 2024 (USD Billion)
  • TABLE 26: UK monoclonal antibodies market, by end-use, 2013 - 2024 (USD Billion)
  • TABLE 27: Asia Pacific monoclonal antibodies market, by source type, 2013 - 2024 (USD Billion)
  • TABLE 28: Asia Pacific monoclonal antibodies market, by production type, 2013 - 2024 (USD Billion)
  • TABLE 29: Asia Pacific monoclonal antibodies market, by indication, 2013 - 2024 (USD Billion)
  • TABLE 30: Asia Pacific monoclonal antibodies market, by end-use, 2013 - 2024 (USD Billion)
  • TABLE 31: Japan monoclonal antibodies market, by source type, 2013 - 2024 (USD Billion)
  • TABLE 32: Japan monoclonal antibodies market, by production type, 2013 - 2024 (USD Billion)
  • TABLE 33: Japan monoclonal antibodies market, by indication, 2013 - 2024 (USD Billion)
  • TABLE 34: Japan monoclonal antibodies market, by end-use, 2013 - 2024 (USD Billion)
  • TABLE 35: China monoclonal antibodies market, by source type, 2013 - 2024 (USD Billion)
  • TABLE 36: China monoclonal antibodies market, by production type, 2013 - 2024 (USD Billion)
  • TABLE 37: China monoclonal antibodies market, by indication, 2013 - 2024 (USD Billion)
  • TABLE 38: China monoclonal antibodies market, by end-use, 2013 - 2024 (USD Billion)
  • TABLE 39: India monoclonal antibodies market, by source type, 2013 - 2024 (USD Billion)
  • TABLE 40: India monoclonal antibodies market, by production type, 2013 - 2024 (USD Billion)
  • TABLE 41: Latin America monoclonal antibodies market, by source type, 2013 - 2024 (USD Billion)
  • TABLE 42: Latin America monoclonal antibodies market, by production type, 2013 - 2024 (USD Billion)
  • TABLE 43: Latin America monoclonal antibodies market, by indication, 2013 - 2024 (USD Billion)
  • TABLE 44: Latin America monoclonal antibodies market, by end-use, 2013 - 2024 (USD Billion)
  • TABLE 45: Brazil monoclonal antibodies market, by source type, 2013 - 2024 (USD Billion)
  • TABLE 46: Brazil monoclonal antibodies market, by production type, 2013 - 2024 (USD Billion)
  • TABLE 47: Brazil monoclonal antibodies market, by indication, 2013 - 2024 (USD Billion)
  • TABLE 48: Brazil monoclonal antibodies market, by end-use, 2013 - 2024 (USD Billion)
  • TABLE 49: Mexico monoclonal antibodies market, by source type, 2013 - 2024 (USD Billion)
  • TABLE 50: Mexico monoclonal antibodies market, by production type, 2013 - 2024 (USD Billion)
  • TABLE 51: Mexico monoclonal antibodies market, by indication, 2013 - 2024 (USD Billion)
  • TABLE 52: Mexico Monoclonal antibodies market, by end-use, 2013 - 2024 (USD Billion)
  • TABLE 53: MEA monoclonal antibodies market, by source type, 2013 - 2024 (USD Billion)
  • TABLE 54: MEA monoclonal antibodies market, by production type, 2013 - 2024 (USD Billion)
  • TABLE 55: MEA monoclonal antibodies market, by indication, 2013 - 2024 (USD Billion)
  • TABLE 56: MEA monoclonal antibodies market, by end-use, 2013 - 2024 (USD Billion)
  • TABLE 57: South Africa monoclonal antibodies market, by source type, 2013 - 2024 (USD Billion)
  • TABLE 58: South Africa monoclonal antibodies market, by production type, 2013 - 2024 (USD Billion)
  • TABLE 59: South Africa monoclonal antibodies market, by indication, 2013 - 2024 (USD Billion)
  • TABLE 60: South Africa monoclonal antibodies market, by end-use, 2013 - 2024 (USD Billion)

List of Figures

  • FIG. 1: Market summary (USD Billion)
  • FIG. 2: Market trends & outlook
  • FIG. 3: Market segmentation & scope
  • FIG. 4: Market driver relevance analysis (Current & future impact)
  • FIG. 5: Market restraint relevance analysis (Current & future impact)
  • FIG. 6: Penetration & growth prospect mapping
  • FIG. 7: SWOT Analysis, By Factor (political & legal, economic and technological)
  • FIG. 8: Porter's Five Forces Analysis
  • FIG. 9: Monoclonal antibodies market technology outlook key takeaways
  • FIG. 10: Monoclonal antibodies market: Source type movement analysis
  • FIG. 11: Global murine market, 2013 - 2024 (USD Billion)
  • FIG. 12: Global chimeric market, 2013 - 2024 (USD Billion)
  • FIG. 13: Global humanized market, 2013 - 2024 (USD Billion)
  • FIG. 14: Global human market, 2013 - 2024 (USD Billion)
  • FIG. 15: Monoclonal antibodies market production type outlook: Key takeaways
  • FIG. 16: Monoclonal antibodies market: Production type movement analysis
  • FIG. 17: Global in vitro market, 2013 - 2024 (USD Billion)
  • FIG. 18: Global in vivo market, 2013 - 2024 (USD Billion)
  • FIG. 19: Monoclonal antibodies market disease outlook: Key takeaways
  • FIG. 20: Monoclonal antibodies market: Disease movement analysis
  • FIG. 21: Global cancer market, 2013 - 2024 (USD Billion)
  • FIG. 22: Global autoimmune diseases market, 2013 - 2024 (USD Billion)
  • FIG. 23: Global inflammatory diseases market, 2013 - 2024 (USD Billion)
  • FIG. 24: Global infectious diseases market, 2013 - 2024 (USD Billion)
  • FIG. 25: Global microbial diseases market, 2013 - 2024 (USD Billion)
  • FIG. 26: Global others market, 2013 - 2024 (USD Billion)
  • FIG. 27: Monoclonal antibodies market end-use outlook: Key takeaways
  • FIG. 28: Monoclonal antibodies market: End-use movement analysis
  • FIG. 29: Global hospitals market, 2013 - 2024 (USD Billion)
  • FIG. 30: Global research institutes market, 2013 - 2024 (USD Billion)
  • FIG. 31: Global others market, 2013 - 2024 (USD Billion)
  • FIG. 32: Regional market place: Key takeaways
  • FIG. 33: Regional outlook, 2015 & 2024
  • FIG. 34: North America monoclonal antibodies market, 2013 - 2024 (USD Billion)
  • FIG. 35: U.S. monoclonal antibodies market, 2013 - 2024 (USD Billion)
  • FIG. 36: Canada monoclonal antibodies market, 2013 - 2024 (USD Billion)
  • FIG. 37: Europe monoclonal antibodies market, 2013 - 2024 (USD Billion)
  • FIG. 38: Germany monoclonal antibodies market, 2013 - 2024 (USD Billion)
  • FIG. 39: UK monoclonal antibodies market, 2013 - 2024 (USD Billion)
  • FIG. 40: Asia Pacific monoclonal antibodies market, 2013 - 2024 (USD Billion)
  • FIG. 41: Japan monoclonal antibodies market, 2013 - 2024 (USD Billion)
  • FIG. 42: China monoclonal antibodies market, 2013 - 2024 (USD Billion)
  • FIG. 43: India monoclonal antibodies market, 2013 - 2024 (USD Billion)
  • FIG. 44: Latin America monoclonal antibodies market, 2013 - 2024 (USD Billion)
  • FIG. 45: Brazil monoclonal antibodies market, 2013 - 2024 (USD Billion)
  • FIG. 46: Mexico monoclonal antibodies market, 2013 - 2024 (USD Billion)
  • FIG. 47: MEA monoclonal antibodies market, 2013 - 2024 (USD Billion)
  • FIG. 48: South Africa Monoclonal antibodies market, 2013 - 2024 (USD Billion)
  • FIG. 49: Strategy framework
  • FIG. 50: Participant categorization
Back to Top